Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Nutranomics, Inc.
DRAPER, Utah, Oct. 4, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to announce that the results of human patient clinical studies undertaken by the Company regarding Glucozyme™ are nearing a public release date. Glucozyme™ is a proprietary nutritional supplement being developed by Nutranomics that has been shown to aid in the processing of sugars to maintain proper glucose and insulin levels in patients with diabetes and pre-diabetes.
Following the conclusion of the latest Glucozyme clinical studies conducted in Japan and Mexico, the resulting new patient data was compiled and compared with previous testing conducted in North America prior to submission for product approval and distribution in several world markets.
"As with all Nutranomics proprietary formulas, Glucozyme is being thoroughly tested for safety and effectiveness prior to release to distributors and the public. In the case of Glucozyme, we will have three separate clinical studies conducted independently of each other in three different countries to support the science behind the product," commented Dr. Tracy Gibbs, CEO of Nutranomics. "Diabetes and pre-diabetes have reached epidemic proportions affecting almost 350 million people worldwide. We all know someone afflicted by diabetes or at serious risk. Following the successful release of results from the clinical studies, Glucozyme will be one step closer to helping patients manage their glucose levels more effectively and potentially prevent diabetes from impacting their lives dramatically."
Nutranomics anticipates that data compilation and analysis from the Glucozyme clinical studies will be made available within the next 2-3 weeks at which time the Company expects to release an additional statement.
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at firstname.lastname@example.org or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the completion of Glucozyme clinical studies in Japan and Mexico, Glucozyme's ability to manage patient glucose levels, and Glucozyme's potential approval for sale in any jurisdiction. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
©2012 PR Newswire. All Rights Reserved.